Pharmaceutical giant Pfizer Inc. currently offers a 6.65% dividend yield and has raised its payout for 15 consecutive years. With an annual dividend of $1.72 per share and a payout ratio of 53.13%, the company maintains one of the strongest balance sheets in the industry. Its diversified portfolio generates substantial cash flow, enabling sustainable distributions even after a pandemic-driven revenue boom that has since normalized. Investors can take comfort in the firm’s liquidity position and its track record of maintaining steady payouts through market cycles.

In a move to enter the weight-loss market, the company completed a $10 billion acquisition of Metsera, positioning itself alongside other billion-dollar players in this rapidly growing segment. Beyond obesity treatments, Pfizer’s late-stage immunology and oncology candidates are slated to enter clinical trials over the next three to five years, underpinning expectations for renewed revenue growth and potential capital appreciation as these drugs advance toward commercialization.

In the most recent quarter, the company reported revenue of $16.65 billion and earnings per share of $0.87. Analyst consensus for the fourth quarter calls for sales of approximately $16.93 billion and EPS of $0.57, with full-year guidance pending release on February 3. Investors will be watching management’s commentary on cost controls, pipeline milestones and any updates to the dividend policy as indicators of the company’s ability to reset growth after pandemic-era highs.